SBL
HQL

Sargent Bickham Lagudis’s abrdn Life Sciences Investors HQL Stock Holding History

Sargent Bickham Lagudis’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-168
Closed -$2K – 1073
2022
Q3 		$2K Buy
168
+4
+2% +$60 ﹤0.01% 882
2022
Q2 		$2K Buy
+164
New +$2.48K ﹤0.01% 922

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
CA
Cornerstone Advisors Asheville, North Carolina $2.72B AUM 22.17% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Sargent Bickham Lagudis's HQL Position: Q4 2022 in Review

Sargent Bickham Lagudis sold out of abrdn Life Sciences Investors (HQL) in Q4 2022, closing a stake of 168 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in HQL in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 80 funds tracked by Wall St. Rank hold HQL as of Q4 2022.

  • Sargent Bickham Lagudis reported no remaining abrdn Life Sciences Investors position as of Q4 2022 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 168 abrdn Life Sciences Investors shares in Q4 2022, an estimated $2K.
  • Sargent Bickham Lagudis first reported a position in abrdn Life Sciences Investors in Q2 2022 and held it in 2 quarters.
  • Sargent Bickham Lagudis's abrdn Life Sciences Investors position peaked at $2K in Q3 2022.
  • 80 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.